124 related articles for article (PubMed ID: 9410074)
1. [Tolerance and safety of carbapenems: the use of meropenem].
Lizasoaín M; Noriega AR
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
[TBL] [Abstract][Full Text] [Related]
2. Carbapenems in serious infections: a risk-benefit assessment.
Norrby SR
Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
[TBL] [Abstract][Full Text] [Related]
4. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
5. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of carbapenem antibacterials.
Norrby SR
Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160
[TBL] [Abstract][Full Text] [Related]
8. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
Cox CE; Holloway WJ; Geckler RW
Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
[TBL] [Abstract][Full Text] [Related]
10. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
11. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Wu Y; Chen K; Shi Z; Wang Q
Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
Norrby SR; Newell PA; Faulkner KL; Lesky W
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():207-23. PubMed ID: 8543496
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.
Norrby SR; Gildon KM
Scand J Infect Dis; 1999; 31(1):3-10. PubMed ID: 10381210
[TBL] [Abstract][Full Text] [Related]
15. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
[TBL] [Abstract][Full Text] [Related]
16. Overall clinical utility of the intramuscular preparation of imipenem/cilastatin.
MacGregor RR
Chemotherapy; 1991; 37 Suppl 2():53-7. PubMed ID: 1879188
[TBL] [Abstract][Full Text] [Related]
17. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
Nelson WK; Rayback PA; Quinones R; Giller RH
Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
Romanelli G; Cravarezza P
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
[TBL] [Abstract][Full Text] [Related]
19. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
20. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Sodhi M; Axtell SS; Callahan J; Shekar R
J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
